Specialties
Cartilage
Specialties
Orthopaedics
Specialties
Shoulder
191 results found in 4ms
Which specialist for supraspinatus tendinopathyWhich specialist for supraspinatus tendinopathy
Structural changes on MRI or ultrasound are common in pain-free shoulders; diagnosis depends on symptoms and functional loss, not imaging. Most cases respond to progressive loading exercises; surgery is warranted only after months of structured physiotherapy without adequate recovery.Structural changes on MRI or ultrasound are common in pain-free shoulders; diagnosis depends on symptoms and functional loss, not imaging. Most cases respond to progressive loading exercises; surgery is warranted only after months of structured physiotherapy without adequate recovery.
ChondroFiller safety across 19,000 real-world treatmentsChondroFiller safety across 19,000 real-world treatments
Across 19,000 real-world treatments, ChondroFiller records no serious adverse device effects and a reoperation rate of 3–8%, compared to 41% for microfracture and 37% for ACI/MACI.Across 19,000 real-world treatments, ChondroFiller records no serious adverse device effects and a reoperation rate of 3–8%, compared to 41% for microfracture and 37% for ACI/MACI.
ChondroFiller durability vs Arthrosamid and hyaluronic acidChondroFiller durability vs Arthrosamid and hyaluronic acid
ChondroFiller's collagen scaffold breaks down in six to twenty-four months, but the clinical benefit lasts one to five years or longer because the material recruits the patient's own progenitor cells to support cartilage repair, not to act as permanent filling.ChondroFiller's collagen scaffold breaks down in six to twenty-four months, but the clinical benefit lasts one to five years or longer because the material recruits the patient's own progenitor cells to support cartilage repair, not to act as permanent filling.
ChondroFiller success rates in practiceChondroFiller success rates in practice
ChondroFiller, which recruits a patient's own cells to fill cartilage defects, produces meaningful pain reduction and improved joint function in 70–85% of patients within one to five years; but success depends on selecting younger patients with focal defects in otherwise healthy joints.ChondroFiller, which recruits a patient's own cells to fill cartilage defects, produces meaningful pain reduction and improved joint function in 70–85% of patients within one to five years; but success depends on selecting younger patients with focal defects in otherwise healthy joints.
Arthrosamid recovery and ankle MFAT in your treatment pathwayArthrosamid recovery and ankle MFAT in your treatment pathway
Arthrosamid is used for knee osteoarthritis and MFAT for ankle cartilage problems or ankle osteoarthritis, but the evidence differs: knee hydrogel data extend to 24 months, while ankle MFAT studies remain early and mostly observational. After Arthrosamid, soreness and swelling usually settle over 24–48 hours, with benefits building over weeks.Arthrosamid is used for knee osteoarthritis and MFAT for ankle cartilage problems or ankle osteoarthritis, but the evidence differs: knee hydrogel data extend to 24 months, while ankle MFAT studies remain early and mostly observational. After Arthrosamid, soreness and swelling usually settle over 24–48 hours, with benefits building over weeks.
ChondroFiller and cortisone treat different knee problemsChondroFiller and cortisone treat different knee problems
Cortisone and ChondroFiller treat different knee problems: cortisone is short-term symptom control for diffuse osteoarthritis or an inflammatory flare, with benefit usually measured in weeks to a few months, while ChondroFiller is a single-stage cell-free collagen scaffold designed for clearly localised grade III or IV cartilage defects and selected osteochondralCortisone and ChondroFiller treat different knee problems: cortisone is short-term symptom control for diffuse osteoarthritis or an inflammatory flare, with benefit usually measured in weeks to a few months, while ChondroFiller is a single-stage cell-free collagen scaffold designed for clearly localised grade III or IV cartilage defects and selected osteochondral lesions. A broadly worn knee should not assume a focal scaffold will help, and a defined cartilage lesion should not assume a cortison...
Targeted Kneecap Pain Relief with Arthrosamid for Patellofemoral OsteoarthritisTargeted Kneecap Pain Relief with Arthrosamid for Patellofemoral Osteoarthritis
Patellofemoral osteoarthritis causes targeted kneecap pain and mobility challenges often overlooked in general knee osteoarthritis care. Arthrosamid, an innovative injectable hydrogel, mimics natural cartilage to cushion the patellofemoral joint, reducing friction and easing discomfort during activities like stair climbing and cycling. Research shows Arthrosamid is safe and effective, especially inPatellofemoral osteoarthritis causes targeted kneecap pain and mobility challenges often overlooked in general knee osteoarthritis care. Arthrosamid, an innovative injectable hydrogel, mimics natural cartilage to cushion the patellofemoral joint, reducing friction and easing discomfort during activities like stair climbing and cycling. Research shows Arthrosamid is safe and effective, especially in older patients with lower osteoarthritis grades and no diabetes. Led by experts like Professor Pau...
191 results found in 4ms